Get the Stockscreener App
347.89
1.61%
-5.8631
United Therapeutics Corp stock is traded at $347.89, with a volume of 119.60K.
It is down -1.61% in the last 24 hours and down -3.94% over the past month.
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
See More
Previous Close:
$353.75
Open:
$355.76
24h Volume:
119.60K
Relative Volume:
0.40
Market Cap:
$15.79B
Revenue:
$2.76B
Net Income/Loss:
$1.11B
P/E Ratio:
15.28
EPS:
22.77
Net Cash Flow:
$898.10M
1W Performance:
-0.89%
1M Performance:
-3.94%
6M Performance:
+8.01%
1Y Performance:
+65.14%
1-Day Range:
$344.39
$357.00
1-Week Range:
$344.36
$358.87
52-Week Range:
$208.62
$417.81
United Therapeutics Corp Stock (UTHR) Company Profile
Name
United Therapeutics Corp
Sector
Industry
Phone
(301) 608-9292
Address
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
347.98 | 15.79B | 2.76B | 1.11B | 898.10M | 22.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.85 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.27 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.13 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.65 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.63 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-12-24 | Upgrade | Goldman | Sell → Neutral |
| Feb-05-24 | Initiated | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Dec-06-22 | Initiated | UBS | Buy |
| Dec-05-22 | Initiated | Goldman | Sell |
| Oct-11-22 | Initiated | Morgan Stanley | Overweight |
| Sep-20-22 | Reiterated | BofA Securities | Underperform |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Feb-11-22 | Initiated | BTIG Research | Neutral |
| Jul-14-21 | Upgrade | Argus | Hold → Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Feb-01-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-14-20 | Resumed | JP Morgan | Overweight |
| Jun-25-20 | Reiterated | H.C. Wainwright | Neutral |
| Mar-10-20 | Upgrade | Jefferies | Hold → Buy |
| Feb-27-20 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-31-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-03-19 | Initiated | BofA/Merrill | Underperform |
| Aug-01-19 | Upgrade | Jefferies | Underperform → Hold |
| Aug-01-19 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-01-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| May-17-19 | Upgrade | UBS | Sell → Neutral |
| May-09-19 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-12-18 | Upgrade | Standpoint Research | Hold → Buy |
| Aug-08-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Apr-03-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Feb-22-18 | Reiterated | Barclays | Underweight |
| Jan-18-18 | Resumed | Credit Suisse | Underperform |
| Dec-27-17 | Reiterated | Wedbush | Outperform |
| Apr-27-17 | Reiterated | Wedbush | Outperform |
| Mar-30-17 | Initiated | UBS | Sell |
| Mar-16-17 | Initiated | Credit Suisse | Underperform |
View All
United Therapeutics Corp Stock (UTHR) Latest News
United Therapeutics president sells $3.5m in stock - MSN
United Therapeutics scores FDA go-ahead for pig organ transplant clinical trial - The Business Journals
State Street Corp Reduces Stake in United Therapeutics Corp - GuruFocus.com
UTHRUnited Therapeutics Corp Latest Stock News & Market Updates - StockTitan
United Therapeutics president sells $3.5m in stock By Investing.com - Investing.com Australia
China Universal Asset Management Co. Ltd. Purchases 909 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
FDA approves pig organ transplant trials for patients with kidney failure - The Washington Post
United Therapeutics Corporation's (NASDAQ:UTHR) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock? - Yahoo Finance
US FDA greenlights clinical trails for pig kidney transplants in humans - MSN
Breakthrough IPF Treatment Study Hits Key Milestone: 598 Patients Enrolled in Game-Changing Tyvaso Trial - StockTitan
US approves trials for pig kidney transplants in humans - NewsBytes
Short Interest in United Therapeutics Co. (NASDAQ:UTHR) Decreases By 14.3% - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) Stock Holdings Raised by Janney Montgomery Scott LLC - MarketBeat
United Therapeutics (NASDAQ:UTHR) Stock Price Down 4.9%Here's What Happened - MarketBeat
FDA approves United Therapeutics' xeno-organ trial - Investing.com
United Therapeutics Corporation Announces FDA Clearance of its Investigational New Drug Application for the UKidney Xenotransplantation Clinical Trial - United Therapeutics Corporation
Revolutionary Pig-to-Human Kidney Transplant Trial Gets Historic FDA Green Light - StockTitan
United Therapeutics Co. (NASDAQ:UTHR) Position Reduced by New England Research & Management Inc. - MarketBeat
Robeco Institutional Asset Management B.V. Sells 4,094 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Milestone Asset Management LLC Raises Holdings in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Swedbank AB Sells 79,432 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
KBC Group NV Acquires 7,169 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
SG Americas Securities LLC Has $1.15 Million Stake in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) COO Sells $3,707,100.00 in Stock - MarketBeat
Manchester gets offer from United Therapeutics to buy nearly 350 acres in Hackett Hill area - AOL
United Therapeutics president sells shares worth $3.7 million By Investing.com - Investing.com South Africa
United Therapeutics president sells shares worth $3.7 million - MSN
Pacer Advisors Inc. Buys 30,931 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Nepsis Inc. Increases Holdings in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Veracity Capital LLC Purchases 1,446 Shares of United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
Nisa Investment Advisors LLC Boosts Holdings in United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
HB Wealth Management LLC Purchases Shares of 1,066 United Therapeutics Co. (NASDAQ:UTHR) - MarketBeat
United Therapeutics Co. (NASDAQ:UTHR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
United Therapeutics plans $96M facility for genetically edited swine in northeast Houston - The Business Journals
United Therapeutics president Michael Benkowitz sells shares worth $3.65m - MSN
United Therapeutics president Michael Benkowitz sells shares worth $3.65m By Investing.com - Investing.com Canada
United Therapeutics Corp Stock (UTHR) Financials Data
Revenue
Net Income
Cash Flow
EPS
United Therapeutics Corp Stock (UTHR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BENKOWITZ MICHAEL | PRESIDENT AND COO |
Feb 03 '25 |
Sale |
353.64 |
10,000 |
3,536,398 |
0 |
| BENKOWITZ MICHAEL | PRESIDENT AND COO |
Jan 27 '25 |
Option Exercise |
111.00 |
10,000 |
1,110,000 |
7,500 |
| BENKOWITZ MICHAEL | PRESIDENT AND COO |
Jan 27 '25 |
Sale |
370.71 |
10,000 |
3,707,081 |
0 |
| BENKOWITZ MICHAEL | PRESIDENT AND COO |
Jan 21 '25 |
Option Exercise |
111.00 |
10,000 |
1,110,000 |
7,500 |
| BENKOWITZ MICHAEL | PRESIDENT AND COO |
Jan 21 '25 |
Sale |
364.91 |
10,000 |
3,649,112 |
0 |
| MAHON PAUL A | EVP & GENERAL COUNSEL |
Jan 16 '25 |
Option Exercise |
163.30 |
7,700 |
1,257,410 |
44,410 |
| BENKOWITZ MICHAEL | PRESIDENT AND COO |
Jan 13 '25 |
Option Exercise |
111.00 |
10,000 |
1,110,000 |
7,500 |
| BENKOWITZ MICHAEL | PRESIDENT AND COO |
Jan 13 '25 |
Sale |
364.62 |
10,000 |
3,646,223 |
0 |
| PATUSKY CHRISTOPHER | Director |
Jan 10 '25 |
Option Exercise |
175.43 |
5,000 |
877,150 |
5,900 |
| PATUSKY CHRISTOPHER | Director |
Jan 10 '25 |
Sale |
361.61 |
5,000 |
1,808,072 |
900 |
3.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):